爪真菌症(爪白癬)(Onychomycosis (Tinea Unguium))の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Onychomycosis (Tinea Unguium) Overview 8
Therapeutics Development 9
Pipeline Products for Onychomycosis (Tinea Unguium) – Overview 9
Pipeline Products for Onychomycosis (Tinea Unguium) – Comparative Analysis 10
Onychomycosis (Tinea Unguium) – Therapeutics under Development by Companies 11
Onychomycosis (Tinea Unguium) – Therapeutics under Investigation by Universities/Institutes 13
Onychomycosis (Tinea Unguium) – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Onychomycosis (Tinea Unguium) – Products under Development by Companies 18
Onychomycosis (Tinea Unguium) – Products under Investigation by Universities/Institutes 19
Onychomycosis (Tinea Unguium) – Companies Involved in Therapeutics Development 20
Actavis plc 20
Anacor Pharmaceuticals, Inc. 21
Eisai Co., Ltd. 22
Evolva SA 23
Helix BioMedix, Inc. 24
Mayne Pharma Group Limited 25
Meiji Seika Pharma Co., Ltd. 26
Moberg Pharma AB 27
NAL Pharmaceuticals Ltd. 28
Nihon Nohyaku Co., Ltd. 29
Novabiotics Ltd 30
Nuvo Research Inc. 31
Viamet Pharmaceuticals, Inc. 32
Onychomycosis (Tinea Unguium) – Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
albaconazole – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AN-2718 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
E-1224 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ELS-160 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
EV-086 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HB-1275 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
itraconazole – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
luliconazole – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ME-1111 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
NAL-3216 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NP-213 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules for Fungal Infections – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
terbinafine – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
terbinafine – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
VT-1161 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Onychomycosis (Tinea Unguium) – Recent Pipeline Updates 64
Onychomycosis (Tinea Unguium) – Dormant Projects 70
Onychomycosis (Tinea Unguium) – Discontinued Products 72
Onychomycosis (Tinea Unguium) – Product Development Milestones 73
Featured News & Press Releases 73
Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis 73
Sep 10, 2014: Data for Viamet’s VT-1161 Presented at ICAAC 2014 73
Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 74
May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015 75
Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis 75
Jun 21, 2012: Mayne Pharma Receives MHRA Approval For Subacap 75
Mar 30, 2012: Palau Pharma Reports Positive Phase IIb Clinical Results Of Albaconazole For Treatment Of Onychomycosis At American Academy Of Dermatology Annual Meeting 76
Feb 14, 2012: NovaBiotics Receives US Patent Further Strengthening Novexatin 77
Feb 09, 2012: Moberg Derma Provides Update On Phase II Study Of MOB-015 77
Dec 15, 2011: Mayne Pharma Provides Update On Subacap European Marketing Approval Application 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80